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suggested that the mechanisms of retrovirus restriction by TRIM5α vary depending on the combination of
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Replication of retroviruses is inﬂuenced by several factors in host
cells. Tripartite motif protein (TRIM) 5α has been identiﬁed as a
restriction factor of human immunodeﬁciency virus type 1 (HIV-1) in
rhesus monkey (Rh) cells (Stremlau et al., 2004). Rh TRIM5α potently
restricts HIV-1 but only weakly does so simian immunodeﬁciency
virus isolated from macaque (SIVmac) (Stremlau et al., 2004; Song et
al., 2005), whereas African green monkey (AGM) TRIM5α can
potently restrict both HIV-1 and SIVmac (Nakayama et al., 2005;
Song et al., 2005). TRIM5α consists of the RING, B-box 2, coiled-coil,
and SPRY (B30.2) domains (Reymond et al., 2001). Differences in the
amino acid sequences in the SPRY domain of TRIM5α of different
monkey species were shown to affect the species-speciﬁc restriction
of retrovirus infection (Perez-Caballero et al., 2005a; Nakayama et al.,
2005; Sawyer et al., 2005; Stremlau et al., 2005; Yap et al., 2005). In
addition, biochemical studies have shown that TRIM5α associates
with retroviral capsid (CA) protein in detergent-stripped virions or
with an artiﬁcially constituted core structure composed of capsid–
nucleocapsid (CA–NC) fusion protein in a SPRY domain-dependent
manner (Sebastian and Luban, 2005; Stremlau et al., 2006a). The SPRY
domain is thus thought to recognize viral core. The coiled-coil domainof TRIM5α is important for the formation of homo-oligomers (Mische
et al., 2005) and is essential for antiviral activity (Javanbakht et al.,
2006). The intact B-box 2 domain is also required for TRIM5α
mediated antiviral activity, since the restrictive activity of TRIM5α is
diminished by amino acid substitutions in the B-box 2 domain
(Javanbakht et al., 2005). RING containing proteins were frequently
found to possess E3 ubiquitin ligase activity (Jackson et al., 2000).
Indeed, Rh TRIM5α was poly-ubiquitinated and degraded rapidly via
the ubiquitin-proteasome pathway, while disruption of the RING
domain eliminated its auto-ubiquitination (Diaz-Griffero et al., 2006).
Furthermore, it was demonstrated that TRIM5α is degraded via the
ubiquitin-proteasome pathway during HIV-1 restriction (Rold and
Aiken, 2008). However, deletion of the RING domain in TRIM5α only
partially attenuates anti-HIV-1 activity (Javanbakht et al., 2005;
Perez-Caballero et al., 2005b). Moreover, modulation of E1 ubiqui-
tin-activating enzyme expression did not affect TRIM5α-mediated
restriction activity in a temperature-dependent cell line (Perez-
Caballero et al., 2005b) and ﬁnally, proteasome inhibitors did not
affect TRIM5α mediated HIV-1 restriction (Anderson et al., 2006;
Perez-Caballero et al., 2005b; Rold and Aiken, 2008; Stremlau et al.,
2006a; Wu et al., 2006) even though they allowed HIV-1 to generate
viral late reverse transcripts under TRIM5α mediated HIV-1 restric-
tion (Anderson et al., 2006; Wu et al., 2006). The exact role of the
TRIM5α RING domain in retrovirus restriction thus remains unclear.
In the study presented here, we investigated the effects of RING
domain mutations on HIV-1 and SIVmac restrictions by TRIM5α and
report that TRIM5α restricts HIV-1 and SIVmac differently.
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Auto poly-ubiquitination of TRIM5α impaired by mutations in
RING domain
The RING ﬁnger domain of TRIM5α comprises eight potential
metal ligands and binds two atoms of zinc, with each zinc atom ligated
tetrahedrally by either four cysteins or three cysteines and a single
histidine. Based on the three-dimensional structure of the RING
domains of TRIM5 (Abe et al., 2007) and the promyelocytic leukemiaFig. 1. Auto poly-ubiquitination of TRIM5αwas impaired by RING domain mutations. (A) Th
shown in circles. Each zinc atom is coordinated tetrahedrally by four ligands. Zinc-binding sit
the zinc-binding cystein and histidine ligands in AGM TRIM5α are also indicated. (B) Prim
human TRIM5α (Hu T5aRING) are aligned. Zinc-binding site 1 (bold), site 2 (italic), and cyste
TRIM5α constructs. Black and white bars denote AGM and Hu sequences, respectively. Abbre
deletion of corresponding amino acid. The positions of individual amino acid changes are al
TRIM5α (TRIM5α-HA) or its RING mutants together with a plasmid expressing myc-tagg
TRIM5α proteins in the lysates were precipitated with an anti-HA antibody. The immunopre
or with anti-myc antibody for ubiquitin detection. Abbreviations: WB, Western blot; IP, im
similar results are shown.(PML) protein (Borden et al., 1995; Borden and Freemont, 1996), the
ﬁrst pair of metal ligands of the AGM TRIM5α RING domain (C15 and
C18) would share a zinc atom with the third pair (C35 and C38), and
the second (C30 and H32) and fourth pairs (C56 and C59)would share
another zinc atom (Fig. 1A). To determine whether anti-HIV-1 and
anti-SIVmac activities of AGM TRIM5α are similarly affected by RING
domainmutations, several AGMTRIM5α constructs withmutations in
the RING domain were generated (Fig. 1B). In the mutant TRIM5α
constructs with C15AC18A, C30AH32A, or C15AC18AC30AH32A, two
key amino acid residues in the ﬁrst or second, or in both the ﬁrst ande RING ﬁnger zinc binding motif. The numbered AGM TRIM5α zinc-binding ligands are
e 1 (bold) and site 2 (italic) are indicated. The numbers of amino acid residues between
ary amino acid sequences of the RING domains of AGM TRIM5α (AGM T5aRING) and
in and histidine ligands (large numbers) are indicated. (C) Schematic representation of
viations for domains: R, RING; B, B-box 2; CC, Coiled-coil; S, SPRY. A dotted box denotes
so indicated. (D) 293 T cells were transfected with plasmids encoding HA-tagged AGM
ed ubiquitin (myc-Ub). Forty-eight hours after transfection, the cells were lysed and
cipitates wereWestern blotted and probed with anti-HA antibody for TRIM5α detection
munoprecipitation. The representative results of two independent experiments with
214 H. Maegawa et al. / Virology 399 (2010) 212–220second zinc-binding sites within the RING domain of AGM TRIM5α
were replaced with alanine residues, respectively. All mutant TRIM5α
constructs contained the HA-tag at their C-terminus (Fig. 1C).
To determine the effects of TRIM5α RING mutations on its
ubiquitin ligase activity, 293T cells were transfected with plasmids
encoding HA-tagged TRIM5αs together with plasmid expressing myc
tagged ubiquitin. Forty-eight hours later, the cells were lysed and
TRIM5α proteins were precipitated with the anti-HA antibody
followed by Western blot analysis using anti-HA and anti-myc
antibodies. Poly-ubiquitinated forms of the wild type AGM TRIM5α
were observed (Fig. 1D). AGM TRIM5α with C15AC18A or C30AH32A
was less poly-ubiquitinated than the wild type AGM TRIM5α, and
AGM TRIM5α with C15AC18AC30AH32A was the least poly-ubiqui-
tinated among the mutant constructs tested. These results conﬁrmedFig. 2. Expression of RINGmutant TRIM5α proteins. (A) Expression of various TRIM5αs. TRIM
(Z), SeVs expressing AGM TRIM5α (AGMWT), AGM TRIM5α C15AC18A (AGM C15AC18A),
C15AC18AC30AH32A), human TRIM5α R332P (Hu R332P), human TRIM5α C15AC18AR332P
by Western blotting with antibody to HA. (B) Subcellular localization of TRIM5αs. CV1 cells
“Materials and methods”. Representative conforcal microscopic images are shown of paren
C30AH32A (d), AGM C15AC18AC30AH32A (e), Hu WT (f), Hu R332P (g), or Hu C15AC18ARthe previously published report (Diaz-Griffero et al., 2006) that the
TRIM5α RING zinc-binding site mutations impaired auto poly-
ubiquitination of TRIM5α.
Contribution of RING domain to retrovirus restriction by AGM TRIM5α
Wenext examined anti-viral activities of zinc-binding sitemutants
of TRIM5α. The HA-tagged wild type and mutant AGM TRIM5α
proteins were expressed by Sendai virus (SeV) in MT4 cells (Fig. 2A).
CV1 cells were then used for a confocal microscopic examination of
cytoplasmic bodies, since the cytoplasm of MT4 cells is not large
enough for observation of cytoplasmic bodies. Each of the TRIM5αs
with RING mutations formed uniformly larger cytoplasmic bodies
than did the wild type (Fig. 2B), although the size of cytoplasmic5α proteins in MT4 cells mock infected (mock) or infected with parental Z strain of SeV
AGM TRIM5α C30AH32A (AGM C30AH32A), AGM TRIM5α C15AC18AC30AH32A (AGM
(Hu C15AC18AR332P), or AGM-TRIM5α-Coiled-coil(−) (AGM CC(−)), were visualized
infected with SeV expressing HA-tagged TRIM5 proteins were analyzed as described in
tal Z strain of SeV (a), or with SeV expressing AGM WT (b), AGM C15AC18A (c), AGM
332P (h).
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These results conﬁrmed the previous observations on Rh TRIM5α
(Javanbakht et al., 2005). Speciﬁcally, AGM TRIM5α with C30AH32A
showed the highest numbers of cytoplasmic bodies and the least
levels of diffuse staining of cytoplasm among the three RING mutants
(Fig. 2B).
For the viral replication assay, MT4 cells infected with SeVs
expressing the wild type and mutant TRIM5αs were also super-
infected with the NL43 strain of HIV-1, GH123 strain of HIV-2 or
SIVmac239. Three days after infection, culture supernatants were
collected and assayed for their levels of p24, p25 or p27 viral CA
protein, respectively. AGM-TRIM5α-CC(−) was used as a negative
control. AGM TRIM5α with C15AC18A, C30AH32A, or C15AC18A-
C30AH32A moderately inhibited HIV-1 growth, while these variants
completely lost their inhibitory effect on SIVmac growth (Fig. 3A).
These results indicated that effects of cysteine substitutions in RING
domain on anti-HIV-1 activity of AGM TRIM5α differ from those on
anti-SIVmac activity, suggesting that SIVmac restriction by AGM
TRIM5αwas totally dependent on the intact RING domain of TRIM5α,
while HIV-1 restriction was at least in part independent from this
domain as reported previously (Javanbakht et al., 2005; Perez-
Caballero et al., 2005b; Stremlau et al., 2004). It has been proposed
that both proteasome-dependent and -independent pathways are
involved in HIV-1 restriction by Rh TRIM5α, since disrupting the
proteasome function by adding a proteasome inhibitor enabled the
generation of normal levels of HIV-1 late reverse transcribed products,
although HIV-1 infection and the generation of nuclear imports of 1-
LTR and 2-LTR viral cDNA forms remained impaired by Rh TRIM5α
(Anderson et al., 2006; Wu et al., 2006). We therefore concluded that
AGM TRIM5α restricts SIVmac mainly via the RING-proteasome-
dependent pathway.
We then tested the third virus, human immunodeﬁciency virus
type 2 (HIV-2), which is more closely related to SIVmac than to HIV-1
(Gao et al., 1999). AGM TRIM5α clearly inhibited HIV-2 GH123
replication and all the RING domain mutants showed reduced anti-
HIV-2 activity. AGM TRIM5αwith C30AH32A completely lost its anti-
HIV-2 activity (Fig. 3A). Unlike SIVmac, however, AGM TRIM5α with
C15AC18A or C15AC18AC30AH32A still moderately inhibited HIV-2
GH123 growth (Fig. 3A). These results indicate that the RING domain
contribution to HIV-2 restriction by TRIM5αwas also distinct from its
contributions to HIV-1 and SIVmac restrictions.
In a single round infection assay, MT4 cells infected with SeVs
expressing the wild type or mutant TRIM5αs variants were super-
infected with HIV-1-GFP or SIVmac-GFP. The wild type AGM TRIM5α
potently restricted both HIV-1-GFP and SIVmac-GFP infection (Fig.
3B) as reported previously (Nakayama et al., 2005). On the other
hand, AGM TRIM5α with C15AC18A, C30AH32A, or C15AC18A-
C30AH32A only moderately inhibited HIV-1-GFP infection, while
these variants completely lost their inhibitory effect on SIVmac-GFP
infection (Fig. 3B). AGM C30AH32A exhibited the weakest anti-HIV-1
activity among the generated mutant constructs, probably due to its
limited localization within the cytoplasm. However, the number of
HIV-1-infected cells was still lower in AGM C30AH32A expressing
cells than in those expressing negative control AGM-TRIM5α-CC(-)
or cells infected with the parental SeV Z strain (Fig. 3B). The same
results as above were obtained when we use canine Cf2Th cell line
lacking endogenous TRIM5α expression (Sawyer et al., 2007) (Fig. 3C).
These results conﬁrmed our results in viral replication assay described
in Fig. 3A.
Contribution of RING domain to retrovirus restriction by human TRIM5α
with arginine-to-proline substitution at the 332nd position
An arginine-to-proline substitution at the 332nd position (R332P)
in the SPRY domain reportedly conferred strong anti-HIV-1 and anti-
SIVmac activities to human TRIM5α (Stremlau et al., 2005; Yap et al.,2005). To determine whether cystein residue substitutions in the
RING domain of human TRIM5αwith R332P (Hu-R332P) have similar
effects on its anti-HIV-1 and anti-SIVmac activities to those of AGM
TRIM5α described above, C15AC18A substitutions were introduced in
Hu-R332P. The protein expression levels of Hu-R332Pwith C15AC18A
were comparable to those of Hu-R332P without C15AC18A (Fig. 2B).
In addition, Hu-R332P inhibited both HIV-1 and SIVmac infection (Fig.
3A, B and C), which conﬁrmed previous ﬁndings (Stremlau et al.,
2005; Yap et al., 2005). As expected, Hu-R332P with C15AC18A
completely lost its auto poly-ubiquitination (Fig. 1D) and anti-SIVmac
activity (Fig. 3A, B and C) indicating that SIVmac restriction by Hu-
R332P also strongly depends on the intact RING domain of TRIM5α. In
contrast to AGM TRIM5α, however, Hu-R332P with C15AC18A
completely lost its anti-HIV-1 activity (Fig. 3A, B and C). These
ﬁndings suggest that, unlike AGM TRIM5α, Hu-R332P TRIM5α
restricted both HIV-1 and SIVmac mainly via a RING-proteasome-
dependent pathway. Hu-R332P TRIM5αwith C15AC18A also failed to
restrict HIV-2 GH123 (Fig. 3A). Taken together with results on AGM
TRIM5α described above, our results indicated that the extent of RING
domain contribution to retrovirus restriction by TRIM5α could be
determined by a combination of virus and host species. We speculate
that the intact RING domain is required for the proteasome-
dependent but not for the proteasome-independent pathway of
TRIM5α restriction of retroviruses.
Effect of proteasome inhibition on antiviral activity of TRIM5α
For a direct investigation of whether AGM TRIM5α restricts
SIVmac and Hu-R332P TRIM5α restricts both HIV-1 and SIVmac
mainly via proteasome-dependent pathway, we used a proteasome
inhibitor MG132. MT4 cells infected with SeVs expressing various
TRIM5α were superinfected with HIV-1-GFP or SIVmac-GFP in the
presence or absence of MG132. After infection, the cells were
thoroughly washed and incubated in MG132-free medium. As
shown in Fig. 4, MG132 had no effect at all on the anti-HIV-1 activity
of AGM, Rh or cynomolgus monkey and of human/AGM chimeric
TRIM5α carrying the SPRY domain of AGM TRIM5α and the RING, B-
box 2, and coiled-coil domains of human TRIM5α. In contrast, and as
expected, MG132 at least partially disrupted the anti-HIV-1 activity of
Hu-R332P TRIM5α. Rh and cynomolgus monkey TRIM5α could not
restrict SIVmac infection and that addition of MG132 did not affect the
numbers of GFP-positive cells, indicating that the condition for
MG132 treatment used in our study did not affect cell viability (Fig.
4). AGM, Hu-R332P and human/AGM chimeric TRIM5α restricted
SIVmac infection while MG132 partially disrupted the anti-SIVmac
activity of those TRIM5α. When we used Cf2Th cells, MG132 also
disrupted the anti-HIV-1 activity of Hu-R332P TRIM5α at least
partially (data not shown). These results support our conclusions
that AGM TRIM5α restricted SIVmac mainly via the proteasome-
dependent pathway, and that Hu-R332P TRIM5α restricted both HIV-
1 and SIVmac mainly via the proteasome-dependent pathway (see
Table 1 for summary of these results).
As described above, the previous studies have shown that
disrupting the proteasome function by adding a proteasome inhibitor
enabled the generation of HIV-1 late reverse transcribed products,
even though HIV-1 infection and the generation of nuclear imports of
1-LTR and 2-LTR viral cDNA forms remained impaired by Rh TRIM5α
(Anderson et al., 2006;Wu et al., 2006).We therefore examined levels
of late reverse transcribed products and 2-LTR forms of HIV-1 cDNA in
TRIM5α-expressing cells by real time PCR method. Mean CT values
(SD) of late reverse transcribed products were 29.80 (0.27), 29.30
(0.15), and 28.11 (0.10) in cells expressing Rh, AGM, and Hu-R332P
TRIM5αs, respectively, while that in control cells was 24.73 (0.08).
These results clearly indicated that synthesis of late reverse
transcribed products were suppressed in cells expressing functional
TRIM5α. When we added MG132, mean CT values (SD) of late reverse
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Fig. 4. The effect of proteasome inhibition on antiviral activity of TRIM5α depends on combinations of TRIM5α and viruses. MT4 cells were infected with SeVs expressing AGM CC
(−), AGM WT, Hu R332P, Hu/AGM, Rh WT or CM WT. Cells were then superinfected with HIV-1-GFP or SIVmac-GFP in the presence of 10 μMMG132 in 0.1% DMSO (black bar) or
0.1% DMSO (gray bar). The representative results of three independent experiments with similar results are shown. Error bars denote actual ﬂuctuations of duplicate samples.
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in cells expressing Rh, AGM, and Hu-R332P TRIM5αs, respectively,
and that in control cells was 24.63 (0.11). Differences between CT
values in the presence of MG132 and those in the absence of MG132
were statistically signiﬁcant (Pb0.05) in cells expressing Rh, AGM,
and Hu-R332P TRIM5αs but not in control cells. We therefore
concluded that slight but signiﬁcant levels of late reverse transcribed
products were recovered by MG132 treatment in cells expressing Rh,
AGM, and Hu-R332P TRIM5αs. It should be noted that we failed to
obtain complete recovery of late reverse transcribed products by
MG132 treatment in our experimental system. This was most likely
caused by incomplete suppression of proteasome function in our
system since SeV-infected MT4 cells could be treated with MG132 for
only 2 h to maintain cell viability, while Hela cells were treated with
MG132 for 15 h in the previous studies (Anderson et al., 2006; Wu et
al., 2006).
With respect to 2-LTR forms of HIV-1 cDNA, mean CT values (SD)
in the absence of MG132 were 39.99 (1.74), 38.32 (2.36), and 37.81
(1.80) in cells expressing Rh, AGM, and Hu-R332P TRIM5αs,
respectively, and that in control cells was 33.68 (0.64). In the
presence of MG132, mean CT values (SD) were 40.02 (1.71), 38.71
(1.39), and 36.46 (2.03) in cells expressing Rh, AGM, and Hu-R332P
TRIM5αs, respectively, and that in control cells was 33.80 (0.28).
Signiﬁcant recovery of 2-LTR forms of HIV-1 cDNA was thus observed
only in cells expressing Hu-R332P TRIM5α (Pb0.05) but not in cells
expressing either AGM or Rh TRIM5αs. These results conﬁrmed that
HIV-1 restriction by Rh and AGM TRIM5αs was both proteasome
dependent and independent while that by Hu-R332P TRIM5α was
mainly proteasome dependent.
Discussion
Deletion of the RING domain or amino acid changes within the
RING domain of Rh TRIM5α has been shown to attenuate anti-HIV-1
activity, but such a mutated TRIM5α still exhibits moderate HIV-1Fig. 3. Contribution by RING domain to retrovirus restriction by TRIM5α depends on combin
(−), AGMWT, AGM C15AC18A, AGM C30AH32A, AGM C15AC18AC30AH32A, Hu R332P, or H
SIVmac239. The culture supernatants were collected three days after infection for measu
experiments with similar results are shown. Error bars denote actual ﬂuctuations of duplica
SeVs expressing AGM WT (black squares), AGM CC(−) (white squares), AGM C15AC18A (
diamonds), Hu R332P (black circles), or Hu C15AC18AR332P (white circles). The cells were
results of two independent experiments with similar results are shown. (C) Canine Cf2Th c
superinfected with HIV-1-GFP or SIVmac-GFP. The representative results of four independe
triplicate samples.restriction (Javanbakht et al., 2005; Perez-Caballero et al., 2005b;
Stremlau et al., 2004). Both proteasome-dependent and -independent
pathways have been proposed in HIV-1 restriction by Rh TRIM5α,
since proteasome inhibitor MG132 allows HIV-1 to generate late
reverse transcribed products, even though HIV-1 infection and the
generation of nuclear 1-LTR and 2-LTR viral cDNA forms remain
impaired by Rh TRIM5α (Anderson et al., 2006;Wu et al., 2006). In the
study presented here, we demonstrated that the contribution of the
RING domain of TRIM5α to retrovirus restriction differed among viral
species. SIVmac completely escaped attacks by RING mutants of
TRIM5α that could still moderately restrict HIV-1 and HIV-2
infection. Addition of proteasome inhibitor MG132 had no effect
at all on the anti-HIV-1 activity of AGM TRIM5α, whereas it
disrupted at least partly the anti-SIVmac activity of AGM TRIM5α.
These results indicate that SIVmac is restricted by AGM TRIM5α
mainly in a proteasome-dependent manner, whereas HIV-1 restric-
tion by AGM, Rh, and cynomolgus monkey TRIM5α is both
proteasome dependent and independent. In case of Hu-R332P
TRIM5α, however, both HIV-1 and SIVmac restrictions were
completely eliminated by mutations in the RING domain. Further-
more, both anti-HIV-1 and anti-SIVmac activities of Hu-R332P
TRIM5α could also be disrupted by the proteasome inhibitor. These
ﬁndings indicate that Hu-R332P TRIM5α restricts both HIV-1 and
SIVmac mainly via the proteasome-dependent pathway.
It was found that TRIM5α could be poly-ubiquitinated and
degraded by the proteasome (Diaz-Griffero et al., 2006). Furthermore,
accelerated turnover of TRIM5α was observed during HIV-1 restric-
tion (Rold and Aiken, 2008). Although there is no direct evidence for
ubiquitination of the virus core by TRIM5α, it is highly likely that
reverse transcription complexes containing viral CA proteins recog-
nized by poly-ubiquitinated TRIM5α would be degraded by the
proteasome in combination with TRIM5α. On the other hand, the
exact molecular mechanism of the proteasome-independent pathway
is still unclear at present. It was previously shown that the incubation
of in vitro assembled CA proteins composed of recombinant HIV-1ation of host and viral species. (A) MT4 cells were infected with SeV expressing AGM CC
u C15AC18AR332P. The cells were then superinfected with HIV-1 NL43, HIV-2 GH123 or
rement of the p24, p25 or p27 levels. The representative results of two independent
te samples. (B) MT4 cells were infected with parental Z strain of SeV (crosses), or with
black triangles), AGM C30AH32A (white triangles), AGM C15AC18AC30AH32A (white
then superinfected with serially diluted HIV-1-GFP or SIVmac-GFP. The representative
ells were infected with SeVs expressing indicated TRIM5α protein. The cells were then
nt experiments with similar results are shown. Error bars denote standard deviation in
Table 1
Summary of TRIM5α-mediated restriction.
Anti-HIV-1 activity Anti-SIVmac activity
TRIM5α proteasome-dependent proteasome-independent proteasome-dependent proteasome-independent
AGM yes yes yes no
AGM C15AC18A no yes no no
AGM with MG132 no yes no no
Hu-R332P yes no yes no
Hu-R332P C15AC18A no no no no
Hu-R332P with MG132 no no no no
Yes, presence of the pathway; no, absence of the pathway.
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TRIM5α B-box, coiled-coil, and SPRY domains and the TRIM21 RING
domain caused apparent breaks in the CA structure without any other
cellular components (Langelier et al., 2008). It is thus likely that direct
binding of Rh TRIM5α proteins to incoming HIV-1 CA proteins causes
CA disassembly, which is observed as proteasome-independent
restriction. AGM TRIM5α would bind both HIV-1 and SIVmac CA,
while it may cause disassembly of the HIV-1 CA but not that of the
SIVmac CA. Similarly, Hu-R332P TRIM5α would bind both HIV-1 and
SIVmac CA but may fail to cause disassembly of both HIV-1 and
SIVmac CAs. We therefore speculate that the proteasome-indepen-
dent pathway requires speciﬁc SPRY–CA interaction that can lead to
CA disassembly.
Although the proteasome inhibitor clearly disrupted anti-HIV-1
activity of Hu-R332P and anti-SIVmac activity of AGM, Hu-R332P, and
human/AGM TRIM5αs, the number of infected cells never reached
the levels of the negative control AGM-TRIM5α-CC(−). Longer
exposure of cells expressing the TRIM5αs with the proteasome
inhibitor did not increase the number of infected cells (data not
shown). In contrast, anti-HIV-1 activity of Hu-R332P and anti-SIVmac
activity of AGM and Hu-R332P TRIM5αs were completely eliminated
by mutations in the RING domain. The reason for this discrepancy is
not clear at present, but it is possible that TRIM5α also exerts a
proteasome-independent but RING-dependent restrictive effect.
The RING-proteasome-independent restriction pathway was ob-
served only in anti-HIV-1 but not in anti-SIVmac activity of AGM
TRIM5α. It is known that cyclophilin A (CypA) binds to HIV-1 CA via
the loop between the 4th and 5th α-helices (L4/5) but not to SIVmac
CA (Luban et al., 1993). Since CypA was reported to restrict HIV-1 in
monkey cells (Berthoux et al., 2005; Keckesova et al., 2006; Nakayama
et al., 2008; Sokolskaja et al., 2006; Stremlau et al., 2006b), it is
possible that CypA binding to HIV-1 CA regulates the RING-
proteasome-independent restriction mechanism of TRIM5α
(Berthoux et al., 2004). This hypothesis prompted us to examine the
effect of the RING mutation of TRIM5α on its restrictive effect on NL-
ScaVR, an HIV-1 derivative containing SIVmac L4/5 of CA and vif
(Kamada et al., 2006). However, NL-ScaVR was similarly restricted by
AGM TRIM5α with C15AC18A to HIV-1 (data not shown), indicating
that neither the CypA-binding site nor vif is the determining factor in
RING-proteasome-independent restriction of HIV-1. Further studies
using various chimeric viruses between HIV-1 and SIVmac will also be
needed to elucidate the exact molecular mechanisms of the RING-
proteasome-independent pathway of TRIM5α mediated HIV-1
restriction.
Conclusion
AGM TRIM5α restricted SIVmac mainly via the proteasome-
dependent pathway, whereas HIV-1 and HIV-2 restriction by AGM
TRIM5α was both proteasome dependent and independent. In
contrast, Hu-R332P restricts both HIV-1 and SIVmac mainly via the
proteasome-dependent pathway. We concluded that the mechanismsof retrovirus restriction by TRIM5α vary depending on the combina-
tion of host and virus.
Materials and methods
Plasmid construction and protein expression
Previous reports have described recombinant Sendai viruses
(SeVs) expressing C-terminally HA-tagged AGM TRIM5α (GenBank
accession number AB210050), Rh TRIM5α (GenBank accession
number AY625001), cynomolgus monkey (CM) TRIM5α (GenBank
accession number AB210052), human TRIM5α (This human TRIM5α
cDNA was obtained from T cell line MT4 and there was a single
glycine-to-aspartic acid substitution at an amino acid position 249
compared with GenBank accession number NM033034.1), human
TRIM5α with R332P, human and AGM chimeric TRIM5α and AGM
TRIM5α lacking the coiled-coil domain (AGM-TRIM5α-CC(−))
(Kono et al., 2008; Maegawa et al., 2008; Nakayama et al., 2005,
2007). In the present study, a PCR-based mutagenesis was used to
generate cDNA of the following C-terminally HA-tagged AGM
TRIM5α RING domain mutants: AGM TRIM5α with C15AC18A,
AGM TRIM5α with C30AH32A, AGM TRIM5α with C15AC18A-
C30AH32A, and human TRIM5α with R332P and C15AC18A muta-
tions. The entire coding sequences of those TRIM5αs were then
transferred to the NotI site of pSeV18+b(+). Recombinant SeVs
expressing various TRIM5αs were obtained with a previously
described method (Shioda et al., 2001).
The plasmid expressing myc-tagged ubiquitin (myc-Ub) was
generated according to the previous publication (Ellison and
Hochstrasser, 1991). Brieﬂy, human ubiquitin cDNA (GenBank
accession number NM_018955) was ampliﬁed by reverse transcrip-
tion-PCR from the human epithelial carcinoma cell line HeLa by using
5′-GCGAATGCCATGACTGAAG-3′ and 5′-GACGTGGTTGGTGATTGGC-3′
followed by nested PCR using 5′-ATGCAGATCTTCGTGAAAACC-3′ and
5′-CTAACCACCTCTCAGACGCAGGACC-3′. The ampliﬁed products were
then cloned into pCR-2.1 TOPO (Invitrogen, Carlsbad, CA). The entire
coding sequences of the myc-Ub were then transferred to the NheI
and NotI site of pcDNA3.1(-) (Invitrogen, Carlsbad, CA).
Immunoprecipitation and Western blot analysis
For protein expression analysis, human T-cell line MT4 was
infected with SeV at a multiplicity of infection (MOI) of 10 plaque
forming units (PFU) per cell, and incubated at 37 °C for 16 h. The cells
were then lysed in RIPA buffer (10 mM Tris–HCl (pH 7.4) containing
100 mM NaCl, 1% Sodium deoxycholate, and 0.1% sodium dodecyl
sulfate), and the cell lysates were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins in
the gel were transferred to a membrane (Immobilon; Millipore,
Billerica, MA), and blots were blocked and probed with an anti-HA
High Afﬁnity rat monoclonal antibody (Roche, Indianapolis, IN)
overnight at 4 °C. Blots were then incubated with peroxidase-
219H. Maegawa et al. / Virology 399 (2010) 212–220conjugated anti-rat IgG (American Qualex, San Clemente, CA). Bound
antibodies were visualized with ChemiLumi-One L chemiluminescent
kit (Nacalai Tesque, Kyoto, Japan).
For ubiquitination analysis, the NotI and EcoRI sites were used to
construct the plasmid expressing HA-tagged TRIM5α RING mutants
in pcDNA3.1(-). DMRIE-C reagent (Invitrogen, Carlsbad, CA) was used
to transfect 293T cells with 1 μg of plasmid encoding HA-tagged wild-
type or mutant TRIM5αs together with 1 μg of plasmid expressing
myc-Ub in six-well plates. Forty-eight hours later, the cells were
lysed and TRIM5α proteins in the lysates were precipitated with a
Protein G-immunoprecipitation kit (Roche, Indianapolis, IN) using
the anti-HA rat monoclonal antibody. After overnight incubation at
4 °C, beads were washed three times in RIPA buffer. Precipitated
proteins were detected with the same procedure as above except that
an anti-myc mouse monoclonal antibody and peroxidase-conjugated
anti-mouse IgG (Kirkegaard and Perry Laboratories, Gaithersburg,
MD) were used for visualizing the myc-tagged Ub protein.
Virus preparation
HIV-1 NL43, HIV-2 GH123 or SIVmac239 was prepared by
transfection of 293T cells with pNL432 (Adachi et al., 1986),
pGH123 (Shibata et al., 1990), or pBRmac239 (Kestler et al., 1991),
respectively. The vesicular stomatitis virus glycoprotein (VSV-G)
pseudotyped HIV-1 vector expressing green ﬂuorescence protein
(GFP) (HIV-1-GFP) was prepared as described previously (Miyoshi et
al., 1997, 1998) as was VSV-G pseudotyped SIVmac vector expressing
GFP (SIVmac-GFP) (Hofmann et al., 1999). The viral titer was
determined by measuring viral CA protein, p24, p25 or p27, with a
RetroTek antigen ELISA kit (ZeptoMetrix, Buffalo, NY).
Viral infection
MT4 or canine Cf2Th cells were infected with SeV expressing
various TRIM5αs. Nine hours after SeV infection, 1.0×105 cells per
dose were superinfected with serially diluted HIV-1-GFPs or SIVmac-
GFPs in 48-well plates and incubated at 37 °C. Forty hours after
infection, the infected cells were ﬁxed with 1% formaldehyde and
counted with a ﬂow cytometer (FACScaliber; Becton Dickinson,
Franklin Lakes, NJ). For the HIV-1, HIV-2 or SIVmac replication
assay, 2.0×105 MT4 cells were infected with SeV expressing various
TRIM5αs and 9 h after SeV infection, the cells were superinfected with
20 ng of p24 of HIV-1 NL43, p25 of HIV-2 GH123 or p27 of SIVmac. The
culture supernatants were collected periodically for measurement of
the p24, p25 or p27 levels.
Proteasome inhibition and infection with HIV-1-GFP or SIVmac-GFP
MT4 cells were infected with SeV expressing various TRIM5αs.
Nine hours after SeV infection, 1.0×105 cells were superinfected with
10 ng of p24 of HIV-1-GFP or 100 ng of p27 of SIVmac-GFP in the
presence of 10 μM MG132 (CALBIOCHEM) in 0.1% DMSO or 0.1%
DMSO only. Two hours after the HIV-1-GFP or SIVmac-GFP infection,
the cells were washed in fresh medium and incubated at 37 °C for
40 h. The infected cells were ﬁxed with 1% formaldehyde and then
counted with a ﬂow cytometer.
Immunoﬂuorescence confocal microscopy
AGM CV1 cells infected with SeV expressing several TRIM5αs at an
MOI of 10 PFU per cell were ﬁxed 24 h after infection in 3%
paraformaldehyde in PBS, permeabilized with 0.05% saponin and 0.2%
bovine serum albumin in PBS, and incubated with the anti-HA rat
monoclonal antibody. Bound antibodies were then detected with a
FITC-conjugated goat antibody directed against rat IgG (American
Qualex Antibodies, San Clemente, CA). Indirect immunoﬂuorescencewas visualized with a Radiance 2000 laser confocal microscope
system (Bio-Rad Laboratories, Hercules, CA).
Real-time PCR analysis
To prepare high titer virus stock of HIV-1 NL43, MT4 cells were
infectedwith NL43 virus and the culture supernatantwas harvested at
its peak titer (1250 ng/ml of p24) at 12 days after infection. Five x 106
MT4 cells were infected with SeV expressing TRIM5α. Twenty hours
after SeV infection, cells were superinfected with 500 μl (625 ng of
p24) of NL43 stock virus with 10 μM MG132 (CALBIOCHEM) in 0.1%
DMSO or with 0.1% DMSO only for 2 h. After washing out of inoculated
virus containing MG132, cells were suspended in 10 ml of ﬂesh media
and incubated at 37 °C for 12 h. Total DNA was extracted by using
QIAamp DNA Blood kit. Real-time PCRwas performedwith an Applied
Biosystems 7500 Real-Time PCR System to analyze viral cDNA
synthesis. Primers and Taqman probes for late reverse transcribed
products and 2-LTR forms were designed according to Julias et al.
(2001) and Van Maele et al. (2003), and 0.6 μg DNAwere subjected to
40 cycles of PCR in 10 μl reaction mixture. Threshold cycle (CT) values
were calculated by 7500 Fast System SDS software (Applied
Biosystems). Mean CT values and their standard deviation (SD) were
calculated in triplicate (late reverse transcribed product) or septupli-
cate (2-LTR) samples. In a few cases we failed to detect ampliﬁcation
of 2-LTR forms, the CT values were assigned as 41 cycles. Statistical
signiﬁcance of observed difference in mean CT values was evaluated
by Mann-Whitney U test.
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